Two Sigma Investments’s Minerva Neurosciences NERV Stock Holding History

Two Sigma Investments’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$129K	Sell	21,394 -900	-4%	-$5.16K	﹤0.01%	4355
2025 Q4	$89.6K	Buy	+22,294	New	+$82.8K	﹤0.01%	3867
2021 Q3	–	Sell	-32,749	Closed	-$608K	–	4543
2021 Q2	$608K	Sell	32,749 -22,114	-40%	-$476K	﹤0.01%	2924
2021 Q1	$1.28M	Buy	54,863 +931	+2%	+$23.3K	﹤0.01%	2087
2020 Q4	$1.01M	Buy	53,932 +28,948	+116%	+$729K	﹤0.01%	2004
2020 Q3	$636K	Buy	+24,984	New	+$675K	﹤0.01%	2062
2020 Q1	–	Sell	-2,313	Closed	-$132K	–	3602
2019 Q4	$132K	Buy	+2,313	New	+$102K	﹤0.01%	3497
2019 Q1	–	Sell	-5,887	Closed	-$317K	–	3332
2018 Q4	$317K	Buy	5,887 +2,797	+91%	+$205K	﹤0.01%	2409
2018 Q3	$310K	Buy	+3,090	New	+$232K	﹤0.01%	2756

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

SSC

Spruce Street Capital New York $416M AUM

Two Sigma Investments's NERV Position: Q1 2026 in Review

Two Sigma Investments reduced its Minerva Neurosciences (NERV) stake by 4% in Q1 2026, selling an estimated $5.16K and leaving 21,394 shares worth $129K. The position accounts for ﹤0.01% of the portfolio, ranked #4355.

Two Sigma Investments first reported a position in NERV in Q3 2018 and has held it in 9 quarters since. The position peaked at $1.28M in Q1 2021. 47 funds tracked by Wall St. Rank hold NERV as of Q1 2026.

Two Sigma Investments held 21,394 shares of Minerva Neurosciences worth $129K as of Q1 2026.
Two Sigma Investments sold 900 Minerva Neurosciences shares in Q1 2026, an estimated $5.16K.
Minerva Neurosciences made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #4355 holding.
Two Sigma Investments first reported a position in Minerva Neurosciences in Q3 2018 and has held it in 9 quarters since.
Two Sigma Investments's Minerva Neurosciences position peaked at $1.28M in Q1 2021.
47 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.